Healthcare of Ontario Pension Plan Trust Fund Sells 247,000 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Healthcare of Ontario Pension Plan Trust Fund decreased its position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 35.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 459,000 shares of the company's stock after selling 247,000 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund owned approximately 0.88% of 4D Molecular Therapeutics worth $4,962,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. nVerses Capital LLC bought a new position in 4D Molecular Therapeutics during the 3rd quarter valued at approximately $40,000. Values First Advisors Inc. bought a new position in 4D Molecular Therapeutics in the third quarter worth about $57,000. China Universal Asset Management Co. Ltd. lifted its holdings in 4D Molecular Therapeutics by 64.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company's stock worth $108,000 after buying an additional 3,922 shares during the period. Proficio Capital Partners LLC purchased a new position in shares of 4D Molecular Therapeutics during the 3rd quarter worth approximately $108,000. Finally, Quest Partners LLC grew its holdings in shares of 4D Molecular Therapeutics by 17,409.1% during the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company's stock worth $121,000 after acquiring an additional 5,745 shares during the period. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

4D Molecular Therapeutics Stock Down 0.4 %

Shares of NASDAQ FDMT traded down $0.03 during midday trading on Friday, hitting $7.84. The stock had a trading volume of 335,675 shares, compared to its average volume of 897,652. The company has a market cap of $362.44 million, a P/E ratio of -2.75 and a beta of 2.82. The business's 50 day moving average is $8.83 and its 200-day moving average is $15.89. 4D Molecular Therapeutics, Inc. has a 52 week low of $7.32 and a 52 week high of $36.25.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on FDMT shares. Royal Bank of Canada dropped their price target on 4D Molecular Therapeutics from $40.00 to $39.00 and set an "outperform" rating on the stock in a research report on Thursday, November 14th. HC Wainwright restated a "buy" rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. Morgan Stanley initiated coverage on shares of 4D Molecular Therapeutics in a research note on Thursday, November 21st. They issued an "underweight" rating and a $8.00 price target for the company. Chardan Capital reissued a "buy" rating and set a $39.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Finally, Cantor Fitzgerald cut shares of 4D Molecular Therapeutics from an "overweight" rating to a "neutral" rating in a report on Monday, September 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $42.13.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.